The contract research market: revenues are growing while vendors are consolidating

Article

Projected growth rates for outsourced work range from 12 to 17%

Two just-released market studies provide scope to the contract research organization (CRO) business, which has seen consolidation in the past year on a scale comparable to the consolidation in other parts of the healthcare universe (insurers, healthcare systems, and, to a degree, the pharma industry itself), even while the business is experiencing double-digit growth.

At Kalorama Information, the Outsourcing in Drug Discovery Market, 8th edition, report projects a 17% growth rate between 2017 and 2018 in the global market, to $27.8 billion. The longer-term trend is for a doubling of the market between 2017 and 2022, when the market will be $48.1 billion.

At The Business Research Co., Contract Research Organizations Global Market Report 2018 finds that the current growth rate is 12% per year globally; also that the US market was worth $20.8 billion in 2017 in a global market of $44.4 billion (obviously, Business Research and Kalorama are using different criteria for their estimations). Both reports find that the outsourced portion of pharma drug development is growing and will reach 50% in the near future.

Business Research’s news release includes a ranking of top CROs and their respective market shares:

1. IQVIA, 12.4%

2. Laboratory Corp., 6.6%

3. ICON PLC, 5.5%

4. Parexel, 4.8%

5. PPD, 4.2%

6. PRA Health Sciences 4.2%

7. Syneos Health 3.7%

8. Charles River Laboratories, 2.6%

9. WuXi Pharmatech, 2.1%

The Kalorama report is available for purchase here, while The Business Research Co.’s report is here.

Newsletter

Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.